Project Grant R01CA285657
Award Date
7/15/24
Completion Date
6/30/29
Dollars Obligated
$627K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (93.395 - Cancer Treatment Research) provides funding to Brigham & Women's Hospital Inc. to develop and extensively test a novel cellular therapy platform for treating glioblastoma (GBM), a highly malignant brain tumor. The $417,858 award, effective January 7, 2025 through December 31, 2029, will support the development of engineered mesenchymal stem cells (MSCs) that release bi-specific T-cell engager (BiTE) molecules...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a Phase I clinical trial of CAR-T cells engineered to secrete a T cell-engaging antibody molecule (CARV3.TEAM-E cells) for the treatment of glioblastoma (GBM), a deadly brain tumor. The key products and services to be delivered under this $652,725 award, with a project...
This federal Project Grant award under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program from the National Institute of Neurological Disorders and Stroke (NINDS) will fund research to improve IL12 immunogene therapy for glioblastoma (GBM). The $633,656 grant awarded on August 22, 2024 will support preclinical studies to investigate: 1) whether the timing of administering immune checkpoint inhibitors (ICI) affects the therapeutic response...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $678,228 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop GLISCAN, a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The project aims to optimize, verify, and validate GLISCAN in adherence with industry standards, with the intention of...
The Project Grant award R01CA292508 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is focused on advancing the understanding and treatment of cancers with mutations in the IDH1 gene. This $693,781 award to the General Hospital Corporation (Massachusetts General Hospital) for the period of April 14, 2025 to March 31, 2030 supports research to: Further study how mutant IDH1 causes cancer growth and how IDH1 inhibitor drugs block cancer...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $794,967 Project Grant (CFDA 93.853) to the Augusta University Research Institute, Inc. to develop a murine glioblastoma model that is permissive to oncolytic herpes simplex virus (oHSV) therapy. The overall goal is to create an immune-competent mouse model that can reproducibly simulate human grade IV brain tumors and be utilized to evaluate the safety and efficacy of oHSV-based biotherapies for this highly aggressive...
This $216,736 federal Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) aims to engineer a biomaterial therapy that locally delivers a retinoic acid-inducible gene I (RIG-I) agonist to elicit a pro-inflammatory response in mouse models of glioblastoma (GBM), an aggressive form of brain cancer. The therapy utilizes a polymeric nanocarrier to deliver a stem-loop 3'-triphosphorylated double-stranded RNA (SLR) compound that activates the RIG-I pathway,...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, provides $678,879 to Cold Spring Harbor Laboratory to conduct research on epigenetic mechanisms that can re-establish tumor suppression in glioblastoma (GBM), the most common and deadly adult primary brain cancer. The key focus of the research is to define the epigenetic mechanism by which targeting the chromatin regulator BRD8 can re-activate the p53 tumor...
The National Cancer Institute (NCI) has awarded a $609,749 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of North Carolina at Chapel Hill (UNC-CH). The 5-year grant supports the development of a novel combinatorial therapy to improve treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products and services to be delivered under this grant include: Creating an injectable, biodegradable hydrogel...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Proton Bio, Inc. for a 12-month period from August 2024 to July 2025. The funding supports research to target the proton-sensing GPR68 receptor as a potential ferroptosis-based therapy for glioblastoma (GBM), the most common and deadly form of adult brain cancer. The key objectives are to: 1) define the in vitro pharmacological properties of lead ogremorphin compound candidates, 2)...